TY - JOUR
T1 - Tumour-associated macrophages
T2 - versatile players in the tumour microenvironment
AU - Ji, Zoey Zeyuan
AU - Chan, Max Kam-Kwan
AU - Chan, Alex Siu-Wing
AU - Leung, Kam-Tong
AU - Jiang, Xiaohua
AU - To, Ka-Fai
AU - Wu, Yi
AU - Tang, Patrick Ming-Kuen
N1 - Funding Information:
The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Research Grants Council of Hong Kong (14106518, 14111019, 14111720, and 24102723); RGC Postdoctoral Fellowship Scheme (PDFS2122-4S06); Hong Kong Government Health and Medical Research Fund (10210726); CU Medicine Passion for Perfection Scheme (PFP202210-004) and Faculty Innovation Award (4620528), CUHK Strategic Seed Funding for Collaborative Research Scheme (178896941), Direct Grant for Research (4054722), Postdoctoral Fellowship Scheme (NL/LT/PDFS 2022/0360/22lt and WW/PDFS 2023/0640/23en).
Publisher copyright:
© 2023 Ji, Chan, Chan, Leung, Jiang, To, Wu and Tang.
PY - 2023/10/26
Y1 - 2023/10/26
N2 - Tumour-Associated Macrophages (TAMs) are one of the pivotal components of the tumour microenvironment. Their roles in the cancer immunity are complicated, both pro-tumour and anti-cancer activities are reported, including not only angiogenesis, extracellular matrix remodeling, immunosuppression, drug resistance but also phagocytosis and tumour regression. Interestingly, TAMs are highly dynamic and versatile in solid tumours. They show anti-cancer or pro-tumour activities, and interplay between the tumour microenvironment and cancer stem cells and under specific conditions. In addition to the classic M1/M2 phenotypes, a number of novel dedifferentiation phenomena of TAMs are discovered due to the advanced single-cell technology, e.g., macrophage-myofibroblast transition (MMT) and macrophage-neuron transition (MNT). More importantly, emerging information demonstrated the potential of TAMs on cancer immunotherapy, suggesting by the therapeutic efficiency of the checkpoint inhibitors and chimeric antigen receptor engineered cells based on macrophages. Here, we summarized the latest discoveries of TAMs from basic and translational research and discussed their clinical relevance and therapeutic potential for solid cancers.
AB - Tumour-Associated Macrophages (TAMs) are one of the pivotal components of the tumour microenvironment. Their roles in the cancer immunity are complicated, both pro-tumour and anti-cancer activities are reported, including not only angiogenesis, extracellular matrix remodeling, immunosuppression, drug resistance but also phagocytosis and tumour regression. Interestingly, TAMs are highly dynamic and versatile in solid tumours. They show anti-cancer or pro-tumour activities, and interplay between the tumour microenvironment and cancer stem cells and under specific conditions. In addition to the classic M1/M2 phenotypes, a number of novel dedifferentiation phenomena of TAMs are discovered due to the advanced single-cell technology, e.g., macrophage-myofibroblast transition (MMT) and macrophage-neuron transition (MNT). More importantly, emerging information demonstrated the potential of TAMs on cancer immunotherapy, suggesting by the therapeutic efficiency of the checkpoint inhibitors and chimeric antigen receptor engineered cells based on macrophages. Here, we summarized the latest discoveries of TAMs from basic and translational research and discussed their clinical relevance and therapeutic potential for solid cancers.
KW - tumour-associated macrophages
KW - tumour microenvironment
KW - immunotherapy
KW - macrophage plasticity
KW - macrophage-myofibroblast transition
KW - macrophage-neuron transition
U2 - 10.3389/fcell.2023.1261749
DO - 10.3389/fcell.2023.1261749
M3 - Review article
C2 - 37965573
SN - 2296-634X
VL - 11
JO - Frontiers in Cell and Developmental Biology
JF - Frontiers in Cell and Developmental Biology
M1 - 1261749
ER -